MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Contributed by: Business Wire

Logo

Tags

Biotechnology

Neurology

Mental Health

Health

Pharmaceutical

MindMed Scientific Presentations at ACNP

More Like This

MindMed to Present at Upcoming May Medical Conferences

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference